Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160(MN) (ALVAC-HIV): A double-blind controlled randomized study of safety and immunogenicity

被引：0
|
作者：
Tubiana, R
Gomard, E
Fleury, H
Gougeon, ML
Mouthon, B
Picolet, H
Katlama, C
机构：
[1] HOP COCHIN,INSERM,U445,F-75674 PARIS,FRANCE
[2] VIROL LAB,BORDEAUX,FRANCE
[3] PASTEUR MERIEUX SERUMS & VACCINS,LYON,FRANCE
[4] INST PASTEUR,PARIS,FRANCE
来源：
AIDS | 1997年 / 11卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：819 / 820
页数：2
相关论文
共 50 条
  • [41] Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents
    Rockstroh, Juergen K.
    Soriano, Vicente
    Plonski, Frank
    Bansal, Meena
    Faetkenheuer, Gerd
    Small, Catherine B.
    Asmuth, David M.
    Pialoux, Gilles
    Mukwaya, Geoffrey
    Jagannatha, Shyla
    Heera, Jayvant
    Pineda, Juan A.
    HIV CLINICAL TRIALS, 2015, 16 (02): : 72 - 80
  • [42] Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection - A randomized, double-blind, placebo-controlled trial
    DAquila, RT
    Hughes, MD
    Johnson, VA
    Fischl, MA
    Sommadossi, JP
    Liou, SH
    Timpone, J
    Myers, M
    Basgoz, N
    Niu, M
    Hirsch, MS
    Costanzo, L
    Ruben, S
    Berzins, B
    Martinez, A
    Fishman, I
    Kazial, K
    Cort, SN
    Robinson, P
    Hall, D
    Macy, H
    McLaren, C
    Rooney, J
    Warwick, J
    CavailleColl, M
    Valentine, F
    Booth, D
    Soeiro, R
    Stein, D
    Zingman, B
    Schliosberg, J
    Polsky, B
    Sepkowitz, K
    Sharpe, V
    Giordano, M
    Wanke, C
    Gulick, R
    Craven, D
    Grodman, C
    Fife, K
    Black, J
    Todd, K
    Nixon, H
    Sperber, K
    Gerits, P
    Mildvan, D
    Nicholas, P
    Murphy, RL
    Kessler, H
    Pulvirenti, J
    ANNALS OF INTERNAL MEDICINE, 1996, 124 (12) : 1019 - 1030
  • [43] Lamivudine in combination with zidovudine stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial
    Kuritzkes, DR
    Marschner, I
    Johnson, VA
    Bassett, R
    Eron, JJ
    Fischl, MA
    Murphy, RL
    Fife, K
    Maenza, J
    Rosandich, ME
    Bell, D
    Wood, K
    Sommadossi, JP
    Pettinelli, C
    AIDS, 1999, 13 (06) : 685 - 694
  • [44] Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trial
    Bobat, R
    Coovadia, H
    Stephen, C
    Naidoo, KL
    McKerrow, N
    Black, RE
    Moss, W
    LANCET, 2005, 366 (9500): : 1862 - 1867
  • [45] Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults
    Sokal, Etienne M.
    Hoppenbrouwers, Karel
    Vandermeulen, Corinne
    Moutschen, Michel
    Leonard, Philippe
    Moreels, Andre
    Haumont, Michele
    Bollen, Alex
    Smets, Francoise
    Denis, Martine
    JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (12): : 1749 - 1753
  • [46] Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Immunogenicity and Safety of a West Nile Virus Vaccine in Healthy Adults
    Biedenbender, Rex
    Bevilacqua, Joan
    Gregg, Anne M.
    Watson, Mike
    Dayan, Gustavo
    JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (01): : 75 - 84
  • [47] Randomized, Placebo-Controlled, Phase I/IIa Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-γ in HIV-1 Infected Subjects
    Emery, S.
    Workman, C.
    Puls, R. L.
    Bloch, M.
    Baker, D.
    Bodsworth, N.
    Anderson, J.
    Crowe, S. M.
    French, M. A. H.
    Hoy, J.
    Aichelburg, A.
    Ward, L. D.
    Boyle, D. B.
    Law, M. G.
    Kelleher, A. D.
    Cooper, D. A.
    HUMAN VACCINES, 2005, 1 (06): : 232 - 238
  • [48] A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults
    Gunale, Bhagwat
    Farinola, Nicholas
    Yeolekar, Leena
    Shrivastava, Shubham
    Girgis, Hanna
    Poonawalla, Cyrus S.
    Dhere, Rajeev M.
    Arankalle, Vidya
    Mishra, Akhilesh Chandra
    Mehla, Rajeev
    Kulkarni, Prasad S.
    VACCINE, 2023, 41 (38) : 5614 - 5621
  • [49] Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study
    Tkachuk, Artem P.
    Bykonia, Evgeniia N.
    Popova, Liubov I.
    Kleymenov, Denis A.
    Semashko, Maria A.
    Chulanov, Vladimir P.
    Fitilev, Sergey B.
    Maksimov, Semyon L.
    Smolyarchuk, Elena A.
    Manuylov, Victor A.
    Vasina, Daria V.
    Gushchin, Vladimir A.
    Gintsburg, Alexander L.
    VACCINES, 2020, 8 (04) : 1 - 17
  • [50] Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial
    Bailon, Lucia
    Llano, Anuska
    Cedeno, Samandhy
    Escriba, Tuixent
    Rosas-Umbert, Miriam
    Parera, Mariona
    Casadella, Maria
    Lopez, Miriam
    Perez, Francisco
    Oriol-Tordera, Bruna
    Ruiz-Riol, Marta
    Coll, Josep
    Perez, Felix
    Leselbaum, Anne R.
    McGowan, Ian
    Sengupta, Devi
    Wee, Edmund G.
    Hanke, Tomas
    Paredes, Roger
    Alarcon-Soto, Yovaninna
    Clotet, Bonaventura
    Noguera-Julian, Marc
    Brander, Christian
    Molto, Jose
    Mothe, Beatriz
    Rivero, Angel
    NATURE MEDICINE, 2022, 28 (12) : 2611 - +
12345